E. Jonsson et al., CYTOTOXIC ACTIVITY OF TOPOTECAN IN HUMAN TUMOR-CELL LINES AND PRIMARYCULTURES OF HUMAN TUMOR-CELLS FROM PATIENTS, British Journal of Cancer, 76(2), 1997, pp. 211-219
The cytotoxic activity and cross-resistance pattern of the novel topoi
somerase I inhibitor topotecan (Topo) were investigated in ten cell li
nes, representing different mechanisms of cytotoxic drug resistance, a
nd in 218 fresh human tumour samples using the fluorometric microcultu
re cytotoxicity assay (FMCA). Resistance to Topo in the cell lines was
associated with expression of the multidrug resistance-associated pro
tein (MRP), whereas the cell lines with P-glycoprotein (P-gp), topoiso
merase II and glutathione-associated resistance did not show decreased
sensitivity to the drug, Topo was more active in haematological than
in solid tumour samples, but substantial activity was observed in carc
inomas of the ovary and breast, sarcoma and childhood solid tumours, C
ross-resistance to standard drugs representing different mechanisms of
action was generally low in patient cells. The effect of Topo was bet
ter after longer exposure, but this time-dependent effect was largely
abolished when adjustment for in vitro exposure was made. Topo showed
activity both in proliferative and non-proliferative cell systems. The
results indicate that Topo is insensitive to major mechanisms of resi
stance except for MRP, Proliferation does not seem to be necessary for
the effect of Topo, and no superiority for protracted dosing schedule
s was observed, The results also suggest that, for example, leukaemias
, lymphomas, sarcomas and childhood solid tumours may be suitable targ
ets for future phase II trials.